- Home
- MVST vs SCPH Comparison
MVST vs SCPH Comparison
Compare MVST & SCPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- SCPH
- Stock Information
- Founded
- MVST 2006
- SCPH 2013
- Country
- MVST United States
- SCPH United States
- Employees
- MVST N/A
- SCPH N/A
- Industry
- MVST Industrial Machinery/Components
- SCPH Biotechnology: Pharmaceutical Preparations
- Sector
- MVST Miscellaneous
- SCPH Health Care
- Exchange
- MVST Nasdaq
- SCPH Nasdaq
- Market Cap
- MVST 848.0M
- SCPH 299.0M
- IPO Year
- MVST N/A
- SCPH 2017
- Fundamental
- Price
- MVST $3.36
- SCPH $5.63
- Analyst Decision
- MVST Strong Buy
- SCPH Buy
- Analyst Count
- MVST 1
- SCPH 3
- Target Price
- MVST $6.00
- SCPH $12.00
- AVG Volume (30 Days)
- MVST 4.9M
- SCPH 2.4M
- Earning Date
- MVST 11-11-2025
- SCPH 11-12-2025
- Dividend Yield
- MVST N/A
- SCPH N/A
- EPS Growth
- MVST N/A
- SCPH N/A
- EPS
- MVST N/A
- SCPH N/A
- Revenue
- MVST $422,605,000.00
- SCPH $49,969,000.00
- Revenue This Year
- MVST $24.21
- SCPH $104.30
- Revenue Next Year
- MVST $31.67
- SCPH $76.06
- P/E Ratio
- MVST N/A
- SCPH N/A
- Revenue Growth
- MVST 20.84
- SCPH 107.79
- 52 Week Low
- MVST $0.15
- SCPH $1.94
- 52 Week High
- MVST $4.72
- SCPH $6.28
- Technical
- Relative Strength Index (RSI)
- MVST 64.48
- SCPH 63.97
- Support Level
- MVST $2.71
- SCPH $4.33
- Resistance Level
- MVST $3.45
- SCPH $5.62
- Average True Range (ATR)
- MVST 0.19
- SCPH 0.04
- MACD
- MVST 0.10
- SCPH -0.01
- Stochastic Oscillator
- MVST 88.88
- SCPH 86.67
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About SCPH scPharmaceuticals Inc.
scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system.